How semaglutide works — and what it actually does inside your body

The common assumption: semaglutide speeds up your metabolism, it doesn't

The biggest misconception people arrive with is that semaglutide must be burning more calories, raising your metabolic rate or blocking fat absorption in some way. It does none of those things. Its primary action is hormonal and neurological: it changes how hungry you feel, and how quickly your body signals that you have eaten enough.

GLP-1 (glucagon-like peptide-1) is a hormone your small intestine secretes in response to food. In people with obesity, this signal can be blunted or short-lived. Semaglutide is a synthetic version of that hormone, engineered to last far longer in the body than the natural molecule, and if you want to understand how semaglutides work at the molecular level, the structural difference between the synthetic and natural forms is the place to start. Where natural GLP-1 degrades within minutes, semaglutide's half-life allows once-weekly dosing while keeping receptor activation sustained throughout the week.

The result is that the appetite-suppressing and satiety-promoting effects are present continuously, not just in the hour after a meal. Many people describe eating noticeably less without consciously trying to, the drive to finish a plate, or to snack between meals, simply quietens. That is the mechanism doing its job, not willpower. If you have been reading about why semaglutide is effective beyond calorie restriction alone, the receptor pharmacology is where the answer lives.

What semaglutide does in the brain, the stomach and the pancreas

Three areas of the body explain most of semaglutide's effects in the context of weight management.

In the hypothalamus, GLP-1 receptors sit within the regions that govern hunger, satiety and reward around food. Sustained activation of these receptors reduces the drive to eat and, in some people, changes how appealing certain foods feel, fatty or very sweet foods often become less attractive. This is not a side effect; it is part of the intended pharmacological action.

In the stomach, semaglutide slows gastric emptying. Food moves from the stomach into the small intestine more slowly, which prolongs the physical sense of fullness after eating and delays the return of hunger signals. This is also why nausea is the most common early side effect: the stomach is adjusting to contents sitting there longer than it expects.

In the pancreas, semaglutide enhances insulin secretion in response to blood glucose and suppresses glucagon, the hormone that raises blood sugar. This is why semaglutide was originally developed for type 2 diabetes. In the weight-management context it contributes to steadier blood-sugar levels, which can reduce the energy dips and cravings that follow glucose spikes. For a fuller picture of how semaglutide drives weight loss specifically, these three pathways work together rather than in isolation.

Does semaglutide actually work, what the evidence says

Semaglutide for weight management has been studied more rigorously than almost any medicine in this class. The STEP programme ran across tens of thousands of participants worldwide, with the landmark STEP 1 trial specifically designed for adults with obesity or overweight without diabetes.

At 68 weeks, the average weight reduction was around 15% of body weight at the 2.4 mg maintenance dose, compared with roughly 2.4% in the placebo group who received the same lifestyle support. That gap is large enough to be clinically meaningful by any standard. NICE recommended semaglutide (Wegovy) for NHS use under Technology Appraisal TA875, citing this evidence base.

It is worth being honest about variation, though. Averages are averages. Some people lose considerably more, some less, and a small proportion see limited response. Semaglutide is not effective in a vacuum: the trials ran alongside lifestyle changes, and the real-world evidence suggests the medicine is most effective when diet and activity are taken seriously alongside it. A prescriber will discuss what realistic expectations look like for your starting point, and if you are curious about how long semaglutide takes to work in practice, that page covers what most people experience across the early weeks and months. You can read more about how Wegovy works specifically, including its dosing schedule and the mechanism behind the escalation phases, on the dedicated overview page.

Semaglutide in the UK: what it's licensed for and how to access it

In the UK, semaglutide for weight management is licensed under the brand name Wegovy, a once-weekly subcutaneous injection made by Novo Nordisk. It is a Black Triangle medicine, meaning the MHRA collects additional safety data while it is in routine use. It is a prescription-only medicine in every form, regardless of where it is sold.

A separate oral formulation, the Wegovy tablet, was approved by the MHRA in June 2026 as the first oral GLP-1 medicine licensed for weight management in the UK. It works via the same GLP-1 mechanism but requires specific administration, taken first thing in the morning on an empty stomach with a small amount of plain water, waiting at least 30 minutes before food or other medicines. The tablet is not interchangeable with the injection without clinical input; which form suits a given person is part of what a prescriber considers.

Ozempic is also semaglutide, but it is licensed for type 2 diabetes, not weight management. Using it off-label for weight loss is not the same as a licensed prescription for Wegovy, and the two should not be conflated.

If you are considering treatment and want to understand the costs involved, the Wegovy pricing page covers what private prescriptions typically include. And if you are ready to talk to a prescriber, a free consultation with the nume clinical team is the natural next step, a named GPhC-registered prescriber reviews every submission the same day it arrives.